Evaluation of the TEG® platelet mapping™ assay in blood donors

被引：94

作者：

Bochsen L. ^{[1
]}

Wiinberg B. ^{[2
]}

Kjelgaard-Hansen M. ^{[2
]}

Steinbrüchel D.A. ^{[3
]}

Johansson P.I. ^{[1
]}

机构：

[1] Department of Clinical Immunology, Rigshospitalet, University of Copenhagen

[2] Department of Small Animal Clinical Sciences, The Small Animal Hospital, University of Copenhagen

[3] Department of Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen

来源：

Thrombosis Journal | / 5卷 / 1期

关键词：

Arachidonic Acid; Clopidogrel; Maximal Amplitude; Antiplatelet Therapy; Platelet Mapping;

D O I：

10.1186/1477-9560-5-3

中图分类号：

学科分类号：

摘要：

Background: Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult because existing platelet function tests are too sophisticated for clinical routine. The whole blood TEG® Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for quantification of platelet function, including the contribution of the adenosine diphosphate (ADP) and thromboxane A2 (TxA2) receptors to clot formation. Methods: In 43 healthy blood donors, the analytical (CVa) and inter-individual variability (CVg) of the TEG® Platelet Mapping™ assay were determined together with platelet receptor inhibition in response to arachidonic acid (AA) and ADP. Results: The CVa of the assay for maximal platelet contribution to clot strength (MAThrombin) was 3.5%, for the fibrin contribution to clot strength (MAFibrin) 5.2%, for MAAA 4.5% and for MAADP it was 6.6%. The MAThrombin CVg was 2.8%, MAFibrin 4.7%, MAAA 6.6% and for MAADP it was 26.2%. Females had a higher MAThrombin compared to males (62.8 vs. 58.4 mm, p = 0.005). The platelet TxA2 receptor inhibition was 1.2% (range 0-10%) and lower than for the ADP receptor (18.6% (0-58%); p < 0.0001). Conclusion: The high variability in ADP receptor inhibition may explain both the differences in response to ADP receptor inhibitor therapy and why major bleeding sometimes develops during surgery in patients not treated with ADP receptor inhibitors. An analytical variation of ∼ 5% for the TEG® enables, however, for routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. © 2007 Bochsen et al; licensee BioMed Central Ltd.

引用

共 20 条

[1]

Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2, J Am Coll Cardiol, 12, (1988)

[2]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, pp. 71-86, (2002)

[3]

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, 348, pp. 1329-1339, (1996)

[4]

Hirsh J., Bhatt D.L., Comparative benefits of clopidogrel and aspirin in high-risk patient populations: Lessons from the CAPRIE and CURE studies, Arch Intern Med, 164, pp. 2106-2110, (2004)

[5]

Bhatt D.L., Aspirin resistance: More than just a laboratory curiosity, J Am Coll Cardiol, 43, pp. 1127-1129, (2004)

[6]

Wang T.H., Bhatt D.L., Topol E.J., Aspirin and clopidogrel resistance: An emerging clinical entity, Eur Heart J, 27, pp. 647-654, (2006)

[7]

Matzdorff A., Platelet function tests and flow cytometry to monitor antiplatelet therapy, Semin Thromb Hemost, 31, pp. 393-399, (2005)

[8]

Tantry U.S., Bliden K.P., Gurbel P.A., Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation, J Am Coll Cardiol, 46, pp. 1705-1709, (2005)

[9]

Craft R.M., Chavez J.J., Bresee S.J., Wortham D.C., Cohen E., Carroll R.C., A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation, J Lab Clin Med, 143, pp. 301-309, (2004)

[10]

Wiinberg B., Jensen A.L., Rojkjaer R., Johansson P., Kjelgaard-Hansen M., Kristensen A.T., Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs, Vet Clin Pathol, 34, pp. 389-393, (2005)

← 1 2 →